Despite many companies showing interest in the UK Innovative Licensing and Access Pathway (ILAP) since it was launched in January 2021, only a few took advantage of the various benefits provided by the scheme, which is set to be revamped early next year.
There was “relatively low uptake of the services on offer” for recipients of the so-called “innovation passport,” which is the entry point to the ILAP,
Key Takeaways
- ILAP, the UK’s flagship initiative that connects the medicines regulator with health technology assessment bodies, is set to be revamped in 2025.
- The pathway aims to deliver safe, effective, financially sustainable, and early patient access to innovative medicines, but companies have so far not used all the tools that the ILAP has to offer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?